AltAssets is the private equity news and research service from Almeida Capital
AltAssets HomeAlmeida Capital websiteAlmeida Capital

Delivering on Discovery
Private Equity Investing in Biotechnology

Delivering on Discovery examines the underlying fundamentals of the industry, the state of the market, the dynamics of private equity investing, and the composition of the different players.

It analyses the appetite and concerns of institutional investors in biotech venture funds, looks at fundraising behaviour, and investigates how successful biotech companies have raised private equity.

The report also strongly challenges the suggestion that a bubble has emerged in the venture sector and identifies the characteristics of the strongest performers going forward. Delivering on Discovery also includes a directory of 600 investors in biotechnology companies. Details include investment strategy, areas of specialisation, geographic focus, experience and funds under management.


Edition: First
Format: Report & Directory
Pages: 188
ISBN: 1-904620-06-X
Published: July 2002

Buy Report Online

Presentation in Adobe PDF Format: WILL BE E-MAILED TO YOU.

£100.00 (Click to Buy)

UK customers: 17.5% VAT will be added to the above price.
EU customers: 17.5% VAT will be added to the above price where a valid VAT number is not supplied by you.
Non- EU customers: No VAT will be added to the above price

NB: Orders can take up to 5 working days to be processed.

Please note, orders can only be cancelled if the product has not yet shipped to you. After products have been dispatched, no refunds can be given. See below for full terms and conditions.

Table of Contents

SECTIONS

  1. Executive Summary
  2. Introduction to Biotechnology
  3. Drivers of the Biotechnology Industry
  4. The Structure of the Biotechnology Industry
  5. Regional Differences in the Biotechnology Industry
  6. Sources of Capital
  7. Private Equity Funds Raised
  8. Private Equity Invested in Biotechnology
  9. Private Equity Investors in Biotechnology
  10. Exits and Returns Characteristics
  11. The Private Equity and Venture Firm Perspective
  12. The Biotechnology Firm Perspective
  13. The Limited Partner Perspective

FIGURES

  1. AltAssets Markets Dynamic Model: Biotechnology
  2. Timeline of Key Biotechnology Events
  3. New Biotech Drug and Vaccine FDA Approvals
  4. Number of Biotech Products in Phase III Trials, 1997-2001
  5. The Average of OECD Countries' Life Expectancy
  6. Growth of Healthcare and Long-term Care Expenditure, as a Percentage of GDP
  7. Key Pharmaceutical Mergers, 1998-2000
  8. Global Pharmaceutical R&D Expenditure, 1990-2000
  9. Average Cost of Drug Development
  10. Typical Creation of a Commercial Biotech Firm)
  11. Number of Biotech Firms in the US
  12. US Biotech Company Revenues 1993-2001
  13. The Leading Biotech Products
  14. Time Taken from Pharmaceutical Testing to New Drug Approval
  15. Examples of Leading Biotech Firms within Sub-sectors
  16. The Process of Bringing a Drug to Market
  17. Largest Pharma and Biotech Companies by Market Cap
  18. Global Breakdown of Biotech Companies
  19. Largest US and European Biotech Companies by Market Cap
  20. Europe's Technology Hotbeds
  21. Biotech Stock Indices vs Internet
  22. Amount Raised by Biotech Firms on US Public Markets
  23. Amount Raised by Biotech Firms via PIPEs
  24. US Venture Investment in Biotech, 1996-2001
  25. Leading Corporate Venturers
  26. The Number of New Biotech-Pharma Alliances, 1993-2001
  27. Value of New Biotech Alliances, 1997-Q3 2001
  28. Biotech Funds in the Market by Fund Target Size
  29. Funds Closed in First Half 2002 Relative to Target
  30. US Biotech Venture Investment as a Share of Total VC Investment, 1995-2002
  31. Number of Investments Into US Biotech and Average Deal Size
  32. Funds Invested in Biotech in Europe, 2000-2002
  33. Number of Investments into European Biotech and Average Biotech Deal Size
  34. Types of Biotech Venture Players
  35. Geographical Breakdown of Biotech Venture Investors
  36. General and Specific Strategies of Biotech Private Equity Firms
  37. Number of Biotech IPOs in the US and Europe, 1996-2001
  38. Value of Biotech IPOs in the US, 1996-2001
  39. Announced Value of Biotech M&A Transactions, 1995-2001
  40. Announced Number of Biotech M&A Transactions, 1995-2001
  41. Return Characteristics of Biotech Venture Capital Funds
  42. VC Preferences vs. Biotech Firm Preferences
  43. Limited Partner Concerns about Investing in Biotechnology

Report Ordering: Delivery, Terms & Conditions and FAQs.

  Advanced Search

HOME | ABOUT US | CONTRIBUTE | FAQ | ADVERTISING | RSS FEED | WEEKLY NEWSLETTER SIGN-UP | CONTACT US

All rights reserved. This document and its content are for your personal, non-commercial use only. No further copying, reproduction, distribution, transmission, display of AltAssets content is allowed. To obtain permission please contact editorial@altassets.com. You may not alter or remove the copyright or any other statements from copies of the content.

AltAssets is a service offered by Almeida Capital's Research Division. Available online at www.AltAssets.net
Almeida Capital Ltd is regulated by FSA and registered in England (no. 3945728). Registered Office: Acre House, 11-15 William Road, London NW1 3ER. Legals & Terms of Use
Content is © AltAssets 2000-2008

Subscribe to our newsletter Subscribe to our newsletter